Refractory Ovarian Carcinoma Completed Phase 1 Trials for Mivavotinib (DB16849)

IndicationStatusPhase
DBCOND0110942 (Refractory Ovarian Carcinoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03756818TAK-659 and Paclitaxel in Treating Patients With Advanced Solid TumorsTreatment